Until now, we have considered treatment selection for EGFR-mutated NSCLC based on the alteration in the gene sequence (primary structure), however, soon, the direction of development for treatment will be based on the structure (tertiary structure). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.